- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: HPV Vaccine Protects for 3 Years; Alzheimer Drug Results; NY Birth Control Law
One dose of human papillomavirus vaccine (HPV) vaccine can prevent infection for at least 3 years, and maybe even longer; Eli Lilly plans to seek FDA approval for Alzheimer drug that slows decline; New York governor signed a bill expanding contraceptive access in the state next year.
One Dose of HPV Vaccine Protects for at Least 3 Years
Just 1 dose of the human papillomavirus vaccine is extremely effective at preventing infections over 3 years, most likely lowering cervical cancer rates and other diseases associated with the virus, according to a new study in Kenya, reported The New York Times. A single-dose strategy would considerably broaden supplies of the vaccine, decrease costs, and simplify distribution that would make vaccination a more feasible option in countries with limited resources, said experts. Protection might extend even longer, reported researchers.
Experimental Drug Slows Alzheimer Decline, Eli Lilly Says
An experimental drug reduced cognitive and functional decline for people with early-stage Alzheimer disease in a new study that could back regulatory approval and commercial sale, according to The Wall Street Journal. Eli Lilly reported new data on donanemab, an intravenous infusion that targets amyloid, and said it plans to apply this quarter to the FDA for approval, with a possible agency decision later this year or the next.
NY Governor Signs Contraceptive Bill
New Yorkers won’t have to go to their doctors to get prescription contraceptives next year under a bill that Democratic Governor Kathy Hochul signed into law Tuesday as part of her administration’s attempts to expand reproductive rights, reported the Associated Press. The law would take effect in November 2024, and trained pharmacists will be able to dispense self-administered hormonal contraceptives like oral birth control pills and the patch to New Yorkers, even if they don’t have a prescription from their doctor or nurse practitioner.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
